Seems like the fund houses agree with me.
Fresh buying seen in Feb 24.
Posts in category Value Pickr
Unihealth Medical Consultancy – The Caplin of Hospitals? (31-03-2024)
As long as I understood the business (I may be wrong)through the concalls and interviews, when they say healthcare consultancy, they mean helping in setting up and then managing those hospitals. This will act as an aseet light business, where in they would use their expertise, contacts and supply chain to mange hospitals effeciently, which would boost their PAT though in a smaller way.
Below is a snap from CRISIL’s credit report.
Microcap momentum portfolio (31-03-2024)
Update for entry on 1st April 2024
As a result of index being rejigged, 70 stocks have been changed. Most of them have gone upward to the Smallcap index. 8 out of 25 and 10 out our top 30 stocks changed and as a result there are 11 changes in our pf mainly as a result of this rejigging.
Based on ranking:
- ELECTCAST
- KPIGREEN
- WOCKPHARMA
- KESORAMIND
- TARC
- VOLTAMP
- NEWGEN
- SANGHVIMOV
- EMUDHRA
- NEULANDLAB
- ARVIND
- MSTCLTD
- KIRLOSENG
- GULFOILLUB
- STAR
- PURVA
- ETHOSLTD
- IFCI
- TIMETECHNO
- ANANTRAJ
- ITDCEM
- CHOICEIN
- MANINFRA
- TVSHLTD
- JKTYRE
Based on A → Z for easy tracking:
- ANANTRAJ
- ARVIND
- CHOICEIN
- ELECTCAST
- EMUDHRA*
- ETHOSLTD
- GULFOILLUB*
- IFCI
- ITDCEM*
- JKTYRE
- KESORAMIND*
- KIRLOSENG
- KPIGREEN*
- MANINFRA*
- MSTCLTD
- NEULANDLAB
- NEWGEN
- PURVA*
- SANGHVIMOV*
- STAR
- TARC*
- TIMETECHNO*
- TVSHLTD*
- VOLTAMP
- WOCKPHARMA
Exit:
ACE, ANANDRATHI, CHENNPETRO, GET&D, HBLPOWER, HSCL, INOXWIND, MAHSEAMLES, PAISALO, RAILTEL and SCHNEIDER exit.
Entry:
EMUDHRA, GULFOILLUB, ITDCEM, KESORAMIND, KPIGREEN, MANINFRA, PURVA, SANGHVIMOV, TARC, TIMETECHNO, TVSHLTD enter.
Smallcap momentum portfolio (31-03-2024)
@krishnasristy NSE gives out press releases with these changes to indices. You have to keep looking out for them.
Unihealth Medical Consultancy – The Caplin of Hospitals? (31-03-2024)
Anti thesis pointer for discussion on this business.
Company is in to following business lines
1.Medical centre and hospital s. In Uganda and in Nigeria…there are 200 operational beds.additional 50 bed planned at Tanzania.Planning for hospitals in India
2.
health care consultancy services -Offers end to end solutions for other groups (presently up to 1000 beds hospital is planned at Pune and Myanmar.Kenya )
3.Distribution of pharma products and consumables.( from India and new syringe manufacturing unit in Tanzania)
4.Medical travel,(health tourism)
Point for discussion :
Hospital business is high margin business and scalable because health care still underpenetrated.i was betting on this vertical of growth…But at the same time company is offering health care consultancy services to other groups to establish hospital. Thus helping it’s competitors to grow in the field… company may earn few negligible revenue in short-term but in long term its not wise decision.At the same time they are telling they want to establish hospitals in India too .
Is it not a contrarian approach?
Am I missing something?
Do we have any revenue split from company about all this?we have to wait for annual report I think .
We have to concentrate on main source of revenue i.e hospital chains
Disclosure: Invested at 150 level.
Smallcap momentum portfolio (31-03-2024)
Notification? Where do u get that?
Shankara Build Pro – Building Materials Organised Retail (31-03-2024)
New stores opened in kartnataka and mahrastra while few closed in kerala.
Net stores count increased to 92 overall.
Smallcap momentum portfolio (31-03-2024)
@krishnasristy I have to monitor them manually, that is why I might miss out some. This is what happened recently. I nearly missed the second notification about IREDA being removed.
Agarwal Industrial Corporation Ltd – Profitable Microcap with high growth potential in infrastructure space (31-03-2024)
Negatives – Bitumen is not a clean business. Bitumen is imported via a lot of illicit routes. The above is general comment on bitumen import and not necessarily Agarwal Industrial. I have no way to check this out for the company.
Plus promoter issuing regular equity to itself, transfer pricing issues further adds to complication.